The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Among patients treated in the first-line setting, the overall response rate was 57.1%, compared with 38.1% in those treated in the second line or later.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete ...

The 30th European Hematology Association (EHA) Congress (EHA 2025), held in Milan, Italy, from June 12-15, 2025, continued ...

Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements ...